

ENS-CCA / Precision-BTC-Network Joint Meeting

June 11-12, 2026

Conference Directors Luke Boulter / Rocio Macias / Chiara Braconi

Local Organizer Konstantinos Athanasopoulos

Day 1	Academia-Pharma Interaction		June 11th 2026
TIME (EEST)	TITLE		SPEAKER
8:00-8:45	Registration, badge & material delivery		
8:45-9:00	Welcome words		Konstantinos Athanasopoulos (Greece)
9:00 - 9:15	ENSCCA 10 Years Reflection		Luke Boulter (UK)
9:15 - 9:30	COST Update/Overview		Rocio Macias (Spain)
9:30 - 10:45 SESSION 1: TRANSLATION INTO CLINICAL DEVELOPMENT: ROLE OF AI IN BIOMARKERS & DIAGNOSTICS			
	<i>Moderators:</i>		<i>Alejandro Forner (Spain) & Tim Kendall (UK)</i>
9:30 - 9:40	Challenges in diagnostics of biliary tract cancers		Pedro Rodrigues (Spain)
9:40 - 10:00	Panel discussion		<i>With the addition of:</i> Jesus Banales (Spain), Stephen Rossi (Spain)
	<i>Moderators:</i>		<i>Anna Saborowski (Germany) & Victor Moreno (Spain)</i>
10:00 - 10:10	Implementation of pathology and molecular biomarkers into clinical practice		Benjamin Goeppert (Germany)
10:10 - 10:20	Navigating clinical trial testing, companion diagnostic development & clinical practice in rare cancers		Brian Lockhart (Servier)
10:20 - 10:45	Panel discussion		<i>With the addition of:</i> Stacie Lindsey (CCF), Benjamin Goeppert (Germany)
10:45 - 11:30 Coffee Break			
11:30-13:00 SESSION 2: PATIENT INVOLVEMENT INTO EARLY TRIALS			
	<i>Moderators:</i>		<i>Angela Lamarca (Spain) & John Bridgewater (UK)</i>
11:30-11:40	Challenges of rare cancers in clinical trials		Arndt Vogel (Germany)
11:40-11:50	Challenges of rare cancers in clinical trials: insights from academic collaboration in BTC & DMG		Katherine Baria (Jazz Pharmaceuticals)
11:50-12:00	Phase 1 trials - Patient views: how can patient advocacy groups impact on trial design?		Juan Valle (CCF)
12:10-12:20	Phase 1 trial success: IDH1 in BTC		Lorenza Rimassa (ILCA member, Italy)
12:20-12:30	How to make academic trials with on-patent drugs successful		John Bridgewater (UK)
12:30 - 13:00	Panel discussion		<i>With the addition of:</i> Helen Morement (AMMF), Matteo Fassan (Italy)
13:00 - 14:30 Lunch Break			
14:30 - 15:30 ORAL ABSTRACTS			
	<i>Moderators:</i>		<i>Rui Castro (Portugal) & Mairead McNamara (UK)</i>
	Exploring the role of ferroptosis in preclinical models of cholangiocarcinoma		Jan Caira David (Portugal)
	Immunopeptidomics of autoimmune biliary disease reveals tumor antigens for cholangiocarcinoma vaccine development		Jandia Aldric (France)
	E2F1-driven metabolic dysregulation is involved in hippo pathway-driven cholangiocarcinoma progression		Kendall Alfaro-Jiménez (Spain)
	MerTK rewires macrophage-tumor crosstalk to drive malignancy in intrahepatic cholangiocarcinoma		Chiara Raggi (Italy)
	Fibrosis-associated procoagulant signaling drives tissue factor expression and thrombosis, impacting survival in intrahepatic cholangiocarcinoma		Luca Fabris (Italy)
15:30 - 16:15 KEYNOTE TALK			
	Introduction		Chiara Braconi (UK)
	Therapeutic development: directions from basic research		Tim Greten (USA)
16:15 - 17:25 SESSION 3: DRUG DEVELOPMENT: NEW TARGETS & COMPOUNDS TO CLINIC			
	<i>Moderators:</i>		<i>Teresa Macarulla (Spain) & Tim Greten (USA)</i>
16:15-16:25	Approach from big pharma: what are you looking for when you invest in a new compound?		Caleb Briggs (AstraZeneca)
16:25-16:35	Approach from smaller biotech: the evolution from academia to industry		Flavia Scialpi (Trogenix, UK)
16:35-16:45	ADCs: where are we going?		Victor Moreno (Spain)
16:45-16:55	Drug development in a patients' niche: how to collaborate between industry and academia?		Kristin Ryan (Elevor Therapeutics, USA)
16:55-17:05	Supporting devices for drug discovery: next-generation preclinical platforms for CCA research		Ana Lleo (Italy)
17:05 - 17:25	Panel discussion		<i>With the addition of:</i> Tian Tian (Spain)
17:25 - 18:15 POSTER TOUR			
	<i>Moderators:</i>		<i>Konstantinos Athanasopoulos (Greece), Pilar Acedo (UK) & Jerzy Kotlinowski (Poland)</i>
20:00 Joint Dinner			

Day 2		Precision-BTC Network Annual Conference		June 12th 2026
TIME	TITLE	SPEAKER		
8:00 - 8:30	Registration, badge & material delivery			
8:30 - 9:30 SESSION 1: WG1 - IDENTIFICATION OF EPIDEMIOLOGICAL HETEROGENEITY IN EUROPE				
	<i>Moderators:</i>	<i>Marcin Krawczyk (Poland) & Lewis Roberts (USA)</i>		
	10 minute presentation + 5 minute discussion			
8:30 - 8:45	Stromal network remodelling shapes immune cell organisation in lymph nodes and tumors	Veronika Lukacs-Kornek (Germany)		
8:45 - 9:00	GLOBAL-BTC registry: expanding the understanding of cancer across the biliary tract	Laura Izquierdo-Sanchez (Spain)		
9:00 - 9:15	A machine learning-powered tool to characterize CCA prognosis	Lorenzo Manganaro (Italy)		
9:15 - 9:30	Personalized prevention & surveillance for cholangiocarcinoma in primary sclerosing cholangitis	Shahid Khan (UK)		
09:30 - 10:30 SESSION 2: WG2 - PERSONALISED EARLY DETECTION OF BTC				
	<i>Moderators:</i>	<i>Guido Carpino (Italy) & Stephanie Roessler (Germany)</i>		
	10 minute presentation + 5 minute discussion			
9:30 - 9:45	Molecular diagnostic solutions for detection of malignant biliary strictures	Michael Dill (Germany)		
9:45 - 10:00	Novel blood metabolomic tests for the diagnosis of primary sclerosing cholangitis and associated CCA	Ainhua Lapitz (Spain)		
10:00 - 10:15	Proteomic profiling of circulating early detection biomarkers in PSC and CCA	Rebeca Correa González (UK)		
10:15 - 10:30	Extracellular matrix remodeling links PSC to cholangiocarcinoma in a sex-dependent manner	Camilla Venturin (Italy)		
10:30-11:00 Coffee Break & Group Photo				
11:00 - 12:00 SESSION 3: WG3 - PERSONALISATION OF TREATMENT FOR PATIENTS WITH BTC				
	<i>Moderators:</i>	<i>Anna Saborowski (Germany) & Elene Mariamidze (Georgia)</i>		
	10 minute presentation + 5 minute discussion			
11:00 - 11:15	Biomarker of adjuvant chemotherapy: data from the BILCAP trial	Chiara Braconi (UK)		
11:15 - 11:30	Insights from real world data from the international community: strategizing the chemoimmunotherapy	Andrea Casadei-Gardini (Italy)		
11:30 - 11:45	Route of diagnosis, onset of symptoms and potential areas of improvement in BTC	Andrea Martirena (Spain)		
12:00 - 13:00 SESSION 4: WG4 - PATIENT-CENTRIC SUPPORT MANAGEMENT				
	<i>Moderators:</i>	<i>Ana Leo (Italy) & Mohamed Bouattour (France)</i>		
	10 minute presentation + 5 minute discussion			
12:00 - 12:15	The role of nursing in cholangiocarcinoma in Europe	Gemma Iserte (Spain)		
12:15 - 12:30	Precision-BTC and EORTC: ongoing collaboration	Antonella Cammarota (Italy)		
12:30 - 12:45	Cholangiocarcinoma patients at the heart of policy	Helen Morement (AMMF)		
12:45 - 13:00	Shining light on hidden cancers: BTC in Europe	Elisabeth Baucells (ATUVIBI)		
13:00-14:30 Lunch Break				
14:30-15:30 SESSION 5: WG5 - ARTIFICIAL INTELLIGENCE				
	<i>Moderator:</i>	<i>Jesper B Andersen (Denmark) & Ghada Nouairia (Sweden)</i>		
	10 minute presentation + 5 minute discussion			
14:30 - 14:45	Update on the molecular registry	Colm O'Rourke (Denmark)		
14:45 - 15:00	AI in iCCA: from diagnosis to treatment decisions	Stefano Caruso (France)		
15:00 - 15:15	Genome-wide methylation profiling from BTCs and PSC using blood DNA provides diagnostic tools and biological insights	Ghada Nouairia (Sweden)		
15:30-16:30 SESSION 6: WG6 - DRUG DEVELOPMENT USING PRECLINICAL MODELS				
	<i>Moderators:</i>	<i>Marta Afonso (Portugal) & Attila Hunyadi (Hungary)</i>		
	10 minute presentation + 5 minute discussion			
15:30 - 15:45	Targeting the desmoplastic stroma in iCCA	Silvia Affo (Spain)		
15:45 - 16:00	Drug discovery with patients derived organoids	Daniela Sia (Mount Sinai, USA)		
16:00 - 16:15	Early neoplastic transition states as targets for precision prevention	Ed Jarman (UK)		
16:15 - 16:30	Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma	Konstantina Morali (Spain)		
16:30 - 16:35	Closing remarks and farewell			